Tag Archives: Ofatumumab

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis Print this page Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically… Read More »

New Drug, Ofatumumab, May Beat Older One at Preventing MS Relapse

WEDNESDAY, Aug. 5, 2020 — A new injection drug can prevent multiple sclerosis flare-ups better than an existing medication, a clinical trial has found. The drug, called ofatumumab, beat a standard MS medication in reducing patients’ symptom relapses. It also slowed down the progression of their disability over six months. The researchers said the findings,… Read More »